Search This Blog

Sunday, February 3, 2019

Geron, Mesoblast, Supernus called buys

Supernus Pharmaceuticals (NASDAQ:SUPN) resumed with Buy rating and $55 (48% upside) price target at Janney.
Mesoblast Limited (NASDAQ:MESO) initiated with Buy rating and $6.50 (43% upside) at H.C. Wainwright.
Geron (NASDAQ:GERN) upgraded to Buy with a $3.25 (216% upside) price target at B. Riley FBR. Shares up 10% premarket.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)